NCT05776134Available不适用
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
- 试验地点
- 44
研究概览
简要总结
The goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is otherwise out of specification for commercial release.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have commercially manufactured brexucabtagene autoleucel that does not meet commercial release criteria but does meet Kite clinical trial release criteria
- •Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been post-menopausal for at least 2 years are not considered to be of childbearing potential)
- •Deemed medically fit and stable to receive the product per the investigator's evaluation
- •Repeat leukapheresis is not feasible per the investigator's assessment
- •Be diagnosed with 1 of the approved labeled indications for brexucabtagene autoleucel that is intended for release
- •In the Investigator's opinion, there is no satisfactory alternative therapy available to the individual
排除标准
- •History of severe immediate hypersensitivity to any drugs or metabolites of similar chemical classes as brexucabtagene autoleucel
- •Uncontrolled active infection or inflammation per physician assessment
- •Primary central nervous system (CNS) lymphoma
研究者
研究点 (44)
Loading locations...
相似试验
Available
不适用
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelLarge B-cell LymphomaFollicular LymphomaNCT05776160Kite, A Gilead Company
Approved For Marketing
不适用
Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell MalignanciesRelapse/Refractory Mantle Cell LymphomaNCT04162756Kite, A Gilead Company
已完成
不适用
AN OPEN-LABEL, MULTI-CENTER, EXPANDED ACCESS STUDY OF TRASTUZUMAB DERUXTECAN IN JAPANESE SUBJECTS WITH HER2-POSITIVE ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMAJPRN-jRCT2080225138DAIICHI SANKYO Co.,Ltd.64
No Longer Available
不适用
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung CancerAdvanced MalignanciesCarcinomaLung CancerNon-small Cell Lung CancerNCT02784158Ariad Pharmaceuticals
Available
不适用
Expanded Access to BurosumabX-linked HypophosphatemiaTumor-Induced OsteomalaciaNCT03775187Kyowa Kirin Co., Ltd.